Best Small Cap Stocks to Trade

Small Cap Stock Alerts in Real Time | No one provides consistent winners like Broad Street!

May 07 2020

Hot sector, Golden cross chart. Technology for the Future of Healthcare (NASDAQ: VUZI)

VUZI Has Tools for the Future of Healthcare

Golden cross formation on the chart, Oversold, Low float, Tele-medicine & wearable tech are both HOT sectors

Good day everyone,

We are initiating coverage of Vuzix Corporation (NASDAQ: VUZI), a company that designs, manufactures, markets, and sells augmented reality (AR) wearable display and computing devices.

Current price $1.75 per share
Outstanding (est.) 33.1 million shares
Float (est.) 27.4 million shares
% Held by Insiders and Institutions approx. 28%
Cash on hand most recent quarter $10.61M
52-week range $.86 to $5.00

We have been watching VUZI shares for a while and feel like right now could be the time to talk about the shares given the current price. After bottoming out in mid-March, VUZI shares have gained some traction, eclipsing their 50 DMA of $1.41 and closing in on their 200 DMA of $1.95. A break past $1.95 may create a catalyst for the company shares to seek a new, higher resistance level.

Trading volumes were strong through April and the shares are leading their SMA 20, both potential indicators of trending shares.

VUZI shares are trading 65% off their 52-week high.

11.9% of the outstanding shares are held by insiders and 15.3% are held by institutions. Insiders with a vested interest in the company and institutions with professionals in tech investments.

Recent analysts target:
3/19/2020 Maxim Group Reiterated Rating Buy $3.50

Vuzix AR wearable display devices are worn like eyeglasses or attach to a head worn mount to view, record, and interact with video and digital content, such as computer data, the Internet, social media, and entertainment applications.

On May 5th, the company announced it has received a replenishment order for M400 Smart Glasses orders from Gemvision to support their efforts to meet COVID-19 remote healthcare needs in the Netherlands.

Two weeks ago, VUZI announced the commercial availability of a turnkey M400 Smart Glasses Remote Worker Connectivity Bundle powered by Sprint Curiosity™ IoT. The new connectivity bundle can offer COVID-19 tele-medicine support in rural hospitals, nursing homes and other remote medical facilities.

Remote healthcare and tele-medicine are the wave of the future. Many of us have already experienced tele-medicine during the Covid 19 pandemic as clinics and doctor’s offices remain somewhat closed.

By utilizing smart-glasses, nurses, EMTs and other front line healthcare providers could call and consult with a doctor while keeping their hands free to perform any treatment.

Wounds can be verbally described, but that is difficult. When a physician can view a wound, it helps greatly. The view of a patient seen by a medical professional wearing smart-glasses could be immediately shared with other members of the care team.

Patients with transmissible diseases, such as Covid 19, could be physically seen by fewer medical professionals, reducing the incidence of transmission, and reducing costs at the same time.

As we all begin to visualize what the world may look like after the Covid 19 pandemic, tele-medicine could play a regular role in healthcare. We believe VUZI could be at the forefront of that new paradigm and we believe the investment community may be evaluating that inevitability as the trend in VUZI shares indicates.

As part of your due diligence you should read this press release: https://finance.yahoo.com/news/telemedicine-usage-vuzix-m400-smart-151100219.html

VUZI offers extraordinary technology, offering benefit to the way we work and live. It is within our nature to resist wearing any kind of extraneous product on our heads (think of face masks). That aversion may be going by the wayside as we realize the benefits of minimal contact in today’s world.

In March, while addressing the current health crisis, the company stated, “there has never been a better time to work hands-free and remotely with AR smart glasses than today.”

The displays (glasses) VUZI sells can be engineered for the industries they partner with. Some partners VUZI has worked with include:

US Department of Defense
Verizon
Qualcomm
Tellus
Sprint

The VUZI intellectual property portfolio consists of over 150 patents.

VUZIX utilizes Waveguide technology. Waveguides are thin (about 1 mm), transparent, optical elements that take a projected virtual image and relay it to the eye while expanding the exit pupil (viewing window) at the same time. Waveguides are transparent, so the smart glasses do not need to be removed to complete other tasks. This is the technology that sets VUZI apart from the competition.

In a significant development, the company recently announced that their M400 Smart Glasses are now supported by Bitnamic, a German-based software company that develops smart services for remote service, inspection, and maintenance of highly complex machines. If the technician wears Vuzix M400 Smart Glasses during the live broadcast, there is no need to look at a smartphone or tablet.

Products
Vuzix Blade Smart-glasses – Blade is a new way to use smart glasses. Waveguide optics project a see-through image to the user. These advanced optics do not obstruct regular vision and allow the user to perfectly switch between the digital world and reality. Sold in two models.

M-Series Smart-glasses – The Vuzix M-Series boasts the new M400 and cost-effective M300XL. Both models are rich in features, including nHD color displays, voice control, touchpad navigation, three axis gyroscope integrated head-tracking, 64GB internal flash memory, and left or right eye use.

Vuzix Labs Smart Swim – Smart Swim™ is a head-up display for swimmers, providing workout status and information about their swim. This enables users to continue uninterrupted and reach optimum performance.

Vuzix Remote Assist – Vuzix Remote Assist (VRA) is a streaming video app optimized for the growing lineup of Vuzix Smart Glasses. VRA increases productivity and customer satisfaction by sharing information between field technicians and remote support experts.

VUZIX also sells a complete line of accessories, apps, and merchandise.

VUZI shares are closing in on their 200-day moving average of $1.95 per share after crossing their 50 DMA last month. A break past these moving averages can mean the shares are ready to find a new, higher resistance level. Recent gains have caused VUZI shares to lead their SMA 20 by 10.9%.

VUZI Chart – https://stockcharts.com/h-sc/ui?s=vuzi

VUZI, as a leader in smart-glasses technology, could be at the forefront of a worldwide trend. Their continuing improvement in their products may expand the markets available to them. We believe their shares may reflect that status in the near term.

The Team

__________________________________________________

Privacy Policy and Disclaimer

Your Consent

By using our site, you consent to our online privacy policy and disclaimer.

Do we disclose any information to outside parties?

We hate spam and we do not sell, trade, or otherwise transfer to outside parties your personally identifiable information.

What information do we collect?

We collect information from you when you subscribe to our newsletter or fill out a form. This includes your email address only.

When registering on our site, as appropriate, you may be asked to enter your: e-mail address

What do we use your information for?

When we collect your email it is used for one purpose to send you the free information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.

Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason whatsoever, other than for the express purpose of delivering the information on small cap stocks that you requested.

We send periodic emails

The email address you provide may be used to send you information, respond to inquiries, and/or other requests or questions.

How do we protect your information?

We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use a secure third party to send email to you.

Because we value your privacy we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act. We therefore will not distribute your personal information to outside parties without your consent.

Online Privacy Policy Only

This online privacy policy applies only to information collected through our website and not to information collected offline.

Contacting Us

If there are any questions regarding this privacy policy or disclaimer you may reply to this email.

DISCLAIMER

This website/newsletter is a wholly owned subsidiary of Small Cap Specialists LLC, herein referred to as SCS LLC.

Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.

PLEASE NOTE WELL: SCS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.

Release of Liability: Through use of this website viewing or using you agree to hold SCS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. SCS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SCS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead SCS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. SCS LLC is compliant with the Can Spam Act of 2003. SCS LLC does not offer such advice or analysis, and SCS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.

The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.

In preparing this publication, SCS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. SCS LLC has been compensate.d fifteen thousand dollars cash via bank wir.e by venado media llc for this weeks coverage of vuzi. The advertisements in this website are believed to be reliable, however, SCS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. SCS LLC is not responsible for any claims made by the companies advertised herein, nor is SCS LLC responsible for any other promotional firm, its program or its structure.
SCS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA.

 

Written by broadAdmin · Categorized: Our Research, Uncategorized

May 01 2020

Join Broad Street Alerts Facebook Group “Small Cap Breakout Stocks”

https://www.facebook.com/groups/975773535841394/

The Team Invites You!

____________________________________________________________________

DISCLAIMER

This website/newsletter is a wholly owned subsidiary of Small Cap Specialists LLC, herein referred to as SCS LLC.

Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.

PLEASE NOTE WELL: SCS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.

Release of Liability: Through use of this website viewing or using you agree to hold SCS LLC, its operator’s owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. SCS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SCS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead SCS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. SCS LLC is compliant with the Can Spam Act of 2003. SCS LLC does not offer such advice or analysis, and SCS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.

The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results.

In preparing this publication, SCS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, SCS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. SCS LLC is not responsible for any claims made by the companies advertised herein, nor is SCS LLC responsible for any other promotional firm, its program or its structure.
SCS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA.

Written by broadAdmin · Categorized: Uncategorized

Apr 18 2017

Why Should You Follow Broad Street Alerts?

Simple, our track record speaks for itself…

 

There are Big Opportunities for the Short and Long Term Trader in Small Cap’s

 

Broad Street Alerts recent profiles in 2017 and track record, 534% in verifiable potential gains for our members on 3 small cap alerts alone!

 

January 31st, 2017- (NASDAQ: HIMX) opened at $5.10/share and hit a high of $9.68/share March 24th, 2017 for gains of 89% within 60 days-

February 6th, 2017- (NASDAQ: SCON) opened at $1.12/share hit a high of $1.80/share within 10 days our member potential gains- 60% –

March 6th, 2017- (OTC: USRM) opened at .035/share and hit over .17/share within 25 days for gains of 385% for our members-

These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So, if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business.

We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.

We do the hard work for you

Most investors don’t have time to track all the companies and do the in depth research and analysis necessary to make solid choices. We do the work for you… because that is our business.

Our picks are solid, real companies

Yes, they’re real businesses with revenues and assets, and real people behind them. Our picks represent real market and business growth potential…not wishes and pipe dreams.

 

***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP – SMS/text alert service for free, simply text the word “Alerts” to the phone number “25827” from your cell phone***

Written by broadAdmin · Categorized: Uncategorized

Apr 03 2017

Cannabics Pharmaceuticals, Inc. (OTCQB: CNBX) Breakthrough Cannabis Medications – Analyst Review

About Broad Street Alerts:

Big Opportunities in Small Cap’s

 

Broad Street Alerts recent profiles and track record, 534% in verifiable potential gains for our members on 3 small cap alerts alone!

 

January 31st, 2017 (NASDAQ: HIMX) opened at $5.10/share and hit a high of $9.68/share March 24th, 2017 for gains of 89% within 60 days-

February 6th, 2017- (NASDAQ: SCON) opened at $1.12/share hit a high of $1.80/share within 10 days our member potential gains- 60% –

 

March 6th, 2017 (OTC: USRM) opened at .035/share and hit over .17/share within 25 days for gains of 385% for our members-

 

These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So, if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business.

 

We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.

 

***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP – SMS/text alert service for free, simply text the word “Alerts” to the phone number “25827” from your cell phone.

Broad Street Alerts Mission Statement

We strive to highlight the future potential as well as the inherent risk in each small cap company we cover while remaining neutral as a leading third-party equity research firm. Please read our privacy policy and full disclaimer below.

 

Cannabics Pharmaceuticals, Inc. (OTCQB: CNBX), is engaged into development of Personalized Anti-Cancer treatments. The Company’s principal product is Cannabics oil capsule that provides a safe, effective and reliable administration of cannabis. The Company’s R&D is based in Israel, where it is licensed by the Ministry of Health for its work in both scientific and clinical research.  On February 2017, CNBX announced it will begin providing personalized cannabinoid anti-tumor tests for cancer patients. The results are expected to enable doctors to make better informed decisions by providing personalized patient data as supporting evidence to available medical treatments.  Through an exclusive collaboration with Cancer Hope Israel, commercialization is expected to commence in March 2017. In 1st phase, CNBX plans to make this service available to cancer patients in Canada, Europe and the USA, under local medical cannabis regulations in each country and state, by the end of 2017.  With these recent developments, CNBX has become one of the few companies in the world who does Cannabinoid scientific research, developing Cannabinoid-based treatments and performing clinical studies for cannabis medicines. Also, it is the first company to offer cancer patients personalized cannabinoid anti-tumor diagnostics.  CNBX operates in Marijuana industry that has rapidly & recently turned into a multi-billion dollar massive growth market across US and Canada with many new states legalizing it. According to a recent estimates, cannabis market crossed $6.7 billion from the U.S. alone in 2016, and that sale of cannabis are set to rise to $22.8 billion in the U.S. by 2020.  The company’s stock has unsurprisingly found enormous strength in the recent past. It has been powering due to the favourable impact of the company’s recent announcements and growing popularity of the industry.

Description & about the Company:

Cannabics Pharmaceuticals Inc. is a US based company founded in 2012 by Israeli researchers from the fields of molecular biology and cancer. CNBX’s entire R&D activities is based in Israel and involves both scientific and academic research as well as current ongoing medical clinical studies which are registered with the US NIH.

Industry developments/progress:

CBD Products, Therapies and Treatments continue to advance through research and development breakthroughs, prompting strong forecast for 2017 performance.

Despite some concerns regarding how the new administration in US is going to favor the Cannabis industry, the perception seems to be changing now. Four states in the U.S. already voted in favor of legalization during November 2016. The results on Election Day confirm that the cannabis industry has a stronger support among Americans than ever before. A study conducted by Pew Research in the U.S. found that the percentage of adults in favor of marijuana legalization is an around 57%.

 

Major product pipeline:
CNBX’s scientific focus is on harnessing the proven therapeutic properties of natural Cannabinoids and to create tailored therapies for cancer patients. The Company’s principal product is Cannabics oil capsule that provides a safe, effective and reliable administration of cannabis. Composed solely from food grade materials, Cannabics oil capsule delivers a steady level of beneficial effects for 4–8 hours.

Recent Break through:
On Feb. 7, 2017, CNBX announced offering personalized cannabinoid anti-tumor tests for cancer patients. The service, based on liquid biopsies, will test patients’ sensitivities to cannabinoid compounds in parallel with conventional chemotherapy. Commercialization will commence next month in the U.S., Europe and Canada.
The aim of the testing is to support doctors’ decisions regarding the best therapies for individual patients. Under an exclusive collaboration agreement with Cancer Hope Israel, the company will provide its proprietary cannabinoid-based compounds to be assessed for their anti-tumor properties.

Also on, January 3, 2017, CNBX announced a New Dosage of 5mg THC Cannabis Capsule Treating Cancer Patients.  The Cannabics 5mg THC capsule is currently being evaluated in a clinical study as a palliative treatment, which is conducted by the oncology department at the Rambam Medical Center in northern Israel and under strict regulations of the Ministry of Health, by whom CNBX has been licensed since 2014.

The majority of CNBX’s cancer trial patients have no previous experience with Cannabis, hence this recalibration of the THC level may be more amenable. Management believe there is a significant potential medical market for its 5mg THC capsule in countries that have now instituted medical cannabis regulations.

These recent breakthroughs in discovering a more potent formulation ratio of cannabis components THC and CBD in combating cancer cells, have enabled CNBX to create marijuana medicines boasting greater efficacy, possibly enjoying a stable share of the medical marijuana market. Aside from that, the company could also generate extra revenues by monetizing its discovery to third-party developers of marijuana medicines.
Key Stock Influences:

Some key influences that might govern future stock price performance include:
(1)    Timely commercialization of CNBX’s personalized cannabinoid anti-tumor tests for cancer patients by next month in the U.S., Europe and Canada.
(2)    CNBX is still a pre-commercial stage biopharmaceutical company and has not yet generated meaningful revenue and will likely operate at a loss as it grows its market position and seeks ways to monetize it.  Therefore, any time or cost overrun in its ongoing R&D activities and its impact on business & financial profile will remain a key business sensitivity factor.
(3)    CNBX is having a constrained financial position. Therefore, its ability to maintain liquidity and financial flexibility to fund its incremental capital requirements will remain a challenge for the company.
(4)    CNBX ability to revamp its sales strategy and to align with mainstream markets would hold the key over the near to medium term.


Earnings Review:

CNBX is still in pre-commercial stage and therefore had no revenue for the three months ended November 30, 2016 and 2015.
For three months ended November 30, 2016, its total operating expenses were $102,876 compared to $52,937 for the three months ended November 30, 2015 resulting in an increase of $49,938. The increase is attributable to increases in general and administrative expenses of $36,694; research and development expenses of $13,736; and a decrease in sales and marketing expenses of $491.

Cash Flow & Balance Sheet:
As of November 30, 2016, the Company had $278,151 in cash. This stands against virtually no total current liabilities. Notwithstanding current cash balances, it is evident that CNBX do not have sufficient resources to effectuate its future business.
Management expects to incur a minimum of $1,000,000 in expenses during the next twelve months of operations. These expenses will be comprised primarily of general expenses including overhead, legal and accounting fees, research and development expenses, and fees payable to outside medical centers for clinical studies.
Therefore, it has to raise significant incremental funds over the near to medium term. It may have to borrow money from shareholders or issue debt or equity or enter into a strategic arrangement with a third party.
Their ability to secure required financing will depend in part upon on investor perception of the company’s ability to create a viable business.

 

Moreover, Capital market conditions and other factors beyond control may also play important roles in their ability to raise capital. The Company can offer no assurance that it will be able to successfully obtain additional financing, or that future financing occurs on terms satisfactory to management and/or shareholders. If funds are unavailable in the future, or unavailable in the amounts that the business requires, or unavailable on acceptable terms, the company may be required to cease operating or modify its business plans in a manner that undermines its ability to achieve business objectives.

Furthermore, factors such as pricing ability, product quality, geographical diversity and product range would also affect the business risk profile of the company.
These weaknesses are partially mitigated by extensive track record of management with strong R&D experience with a particular emphasis on clinical development. Management’s adequate knowledge and network in the field of drug development will play a significant role in advancing CNBX’s products through the clinical and regulatory process.

Stock Performance

 

On Friday, February 17th, 2017, CNBX shares surged by 36.52% to $4.0 on an average volume of 936,967.00 shares exchanging hands. Market capitalization is $662.13 million. The current RSI is 91.08.

In the past 52 weeks, shares of CNBX have traded as low as $0.021 and as high as $4.41.

At $4, shares of CNBX are trading above their 50-day moving average (MA) at $0.96 and above their 200-day MA at $0.38.

The present support and resistance levels for the stock are at $2.8 & $4.77 respectively.

 

Disclaimer

Broad Street Alerts is a wholly owned subsidiary of small cap specialists LLC, herein referred to as SCS LLC.

SCS LLC has not been compensated for this report by anyone and the opinions if any are that of the author Vikas Agrawal, CFA. Author’s Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I, wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in the article.

Written by broadAdmin · Categorized: applenews, Uncategorized

Mar 21 2017

Marijuana Company of America Inc. (OTC: MCOA) Analyst Report

About Broad Street Alerts:

Big Opportunities in Small Cap’s

 

Broad Street Alerts recent profiles and track record, 534% in verifiable potential gains for our members on 3 small cap alerts alone!

 

January 31st, 2017 (NASDAQ: HIMX) opened at $5.10/share and hit a high of $9.68/share March 24th, 2017 for gains of 89% within 60 days-

February 6th, 2017- (NASDAQ: SCON) opened at $1.12/share hit a high of $1.80/share within 10 days our member potential gains- 60% –

March 6th, 2017 (OTC: USRM) opened at .035/share and hit over .17/share within 25 days for gains of 385% for our members-

 

 

These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So, if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business.

 

We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.

 

***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP – SMS/text alert service for free, simply text the word “Alerts” to the phone number “25827” from your cell phone.

Broad Street Alerts Mission Statement

We strive to highlight the future potential as well as the inherent risk in each small cap company we cover while remaining neutral as a leading third-party equity research firm.

 

MCOA Report:

Marijuana Company of America Inc. (OTC: MCOA) is a cannabis marketing and distribution company that distributes medical cannabis products providing product sourcing, branding, payment, distribution and knowledge.

 

During February 2017, MCOA announced that it entered into a non-binding LOI while performing due diligence to finalize a joint venture agreement with Bougainville Ventures, Inc. for the purpose of housing tenant growers engaging in the cultivation, processing and commercial availability of legal marijuana in the State of Washington.

Subject to final agreement, MCOA will invest up to $1 million in JV for 50% equity ownership and share in profits. While, Bougainville Ventures, Inc. will contribute its expertise in establishing the facilities.

 

During 2016, MCOA launched its flagship wellness product called hempSMART Brain. It’s a CBD product combined with a bunch of branded ingredients, and it can purportedly improve brain function and brain health. Management plans to distribute its product through a Multi Level Marketing (MLM) program.

MCOA’s MLM model might have the company positioned better than other cannabis names in the industry. California, Massachusetts, Maine, and Nevada voted to legalize marijuana for recreational use, while North Dakota, Arkansas, Montana, and Florida voted for medical use. This creates plenty of opportunities for MCOA to recruit new members and sell its hempSMART brand of products.

 

MCOA operates in Marijuana industry that has rapidly & recently turned into a multi-billion dollar massive growth market across US and Canada with many new states legalizing it. According to a recent estimates, cannabis market crossed $6.7 billion from the U.S. alone in 2016, and that sale of cannabis are set to rise to $22.8 billion in the U.S. by 2020.  Also, Combined recreational cannabis sales could total an estimated $40-$45 billion, if cannabis is legalized across the United States of America.

The company’s stock has unsurprisingly found some strength in the recent past. It has been powering due to the favorable impact of the company’s recent announcements and growing popularity & demand of the industry.

Description & about the Company:

Marijuana Company of America Inc. (OTC: MCOA) was founded in 2015 and is headquartered in Southern California. MCOA provides product sourcing, branding, payment, distribution, and knowledge base through architecture to maintain customer loyalty and capture market share. MCOA is developing a unique member-only state-by-state club operation for the purposes of better serving individuals desiring to get all the benefits of cannabis. Club members and affiliates in legal medicinal or adult use states will use its app or website to place their order for next-day delivery. MCOA’s CBD line will be available to club members in all 50 states and internationally. The company’s CEO is Donald Steinberg, who was the founder of Medical Marijuana Inc (OTCMKTS:MJNA).

 

 

 

Major product & divisions:

HempSMART: HempSMART brand, represents MCOA’s non-THC, hemp derived, product line. HempSMART products are formulated wit cannabinoid base that is derived from hemp. hempSMART Brain is formulated with CBD or Cannabidiol as the core ingredient combined with high quality branded ingredients to compliment the CBD to support brain health. This is a first-of-its-kind product with a synergistic blend of natural brain support ingredients, blended with water soluble CBD to provide optimal bioavailability for brain support and protection.

 

Club Harmoneous: It is a multi level marketing (MLM) model for Distribution of MCOA products, as a sort of run-your-own-business program. Through this, MCOA’s offers Marketing Services designed to increase membership. This is done through an affiliate referral program where members refer new member patients and earn discounts and income.

Cultivation and processing: Last month, MCOA entered into a Letter of Intent with Bougainville Ventures, Inc. for the purpose of housing tenant growers engaging in the cultivation, processing and commercial availability of legal marijuana in the State of Washington.

Recent announcements:

MCOA recently announced that it has entered into a non-binding Letter of Intent while performing due diligence to finalize a joint venture agreement with Bougainville Ventures, Inc. for the purpose of housing tenant growers engaging in the cultivation, processing and commercial availability of legal marijuana in the State of Washington

 

According to the release, MCOA will invest up to $1 million in cash in a newly formed entity and receive 50% equity ownership and 50% share in net profits produced by the joint venture. Bougainville Ventures, Inc. will contribute its expertise in establishing facilities related to the production, processing and management for tenant growers utilizing an I-502 Tier 3 license, with leased property, established partnerships, licensing agreements and marketing relationships.

 

Expected synergies:

Management confirmed that partnership would allow them to produce high quality products at the lowest possible prices, thereby benefiting their supply chain. Management is of the view that such partnerships would allow them to cultivate superior products in each state, whilst remaining within the state laws.

 

About Bougainville Venture Inc (JV Partner):

Bougainville Venture Inc., is in the core business of converting irrigated farmland that was traditionally used to grow marginally profitable feed crops, to greenhouse-equipped farmland used to grow luxury crops with a primary focus on marijuana. Bougainville offers fully built out turnkey solutions to licensed I-502 tenant-growers and luxury crop growers who will lease the facilities for production and processing.

 

Previous announcements:

Previously, MCOA also announced that it has successfully retained the services of 420 Pros, for the provision of marketing and branding services, for its hempSMART and Club Harmoneous products. Furthermore, it is expected that MCOA would attend a number of expos and trade shows across the country, in the near future, in a bid to reach a larger market.

 

The company also engaged a CPA firm to complete a two-year audit of its financial statements as part of the process of preparing to become a fully reporting public company with the intent of uplisting to a higher reporting exchange.
Key Stock Influences:

Some key influences that might govern future stock price performance include:

  • MCOA’s distribution strategy is still at a very nascent stage. Though, the initial product is on shelves, and the program is underway. MCOA’s ability to revamp its sales strategy and to align with mainstream markets would hold the key over the near to medium term.
  • MCOA’s ability to maintain its liquidity and financial flexibility to fund its incremental capital requirements. Since cannabis is still illegal at federal level, and only selective states have passed legislation to legalize cannabis for medical purposes, it is not easy for MCOA to access capital on agreeable terms. Also, any additional equity raise is exposed to significant dilution risk.
  • Company’s ability to timely deliver under its signed contract for cultivation and processing.


Earnings Review:

The company is in the process of reporting its latest financials. As of September 30, 2016, the Company has generated no revenue per its financial statements.

 

Liquidity and Capital Resources:

At September 30, 2016, the Company’s had limited liquidity and cash reserves. From the date of inception until September 30, 2016, the Company has incurred losses of $4,782,071.

 

The Company’s ability to continue as a going concern is dependent upon its ability to develop additional sources of capital and ultimately to achieve profitable operations.

 

On Monday, March 13th, 2017, MCOA shares declined by -5.2% to $0.0540 on an average volume of 10.01 shares exchanging hands. Market capitalization is $95.70 million. The current RSI is 24.44.

In the past 52 weeks, shares of MCOA have traded as low as $0.00 and as high as $0.20.

At $0.0540, shares of MCOA are trading below their 50-day moving average (MA) at $0.07 and above their 200-day MA at $0.04.

The present support and resistance levels for the stock are at $0.0520 & $0.580 respectively.

 

 

 

 

Disclaimer

Broad Street Alerts is a wholly owned subsidiary of Small Cap Specialists LLC, herein referred to as SCS LLC.

SCS LLC has not been compensated for this report by anyone and the opinions if any are that of the author Vikas Agrawal, CFA. Author’s Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I, wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in the article.

 

 

Written by broadAdmin · Categorized: applenews, Uncategorized

  • 1
  • 2
  • 3
  • …
  • 172
  • Next Page »

Privacy Policy and Disclaimer

Transparency is very important to us.

Please view our full privacy policy and disclaimer below.

 

 

 

Privacy Policy and Disclaimer
Your Consent
By using our site, you consent to our online privacy policy and disclaimer.
Do we disclose any information to outside parties?
We do not sell your information to anyone.
What information do we collect?
We collect information from you when you subscribe to our newsletter or fill out a form on one of our social platforms. This includes your email address and or mobile phone number.
When registering on our site, as appropriate, you may be asked to enter your: e-mail address and or mobile number.
What do we use your information for?
When we collect your email or mobile number it is used for one purpose to send you the information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.
Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason, other than our CRM providers for the express purpose of delivering the information on stocks that you requested.
We send periodic emails.
The email address you provide may be used to send you information, the small cap stock reports you requested, respond to inquiries, and/or other requests or questions.
How do we protect your information?
We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use secure third parties to send email and SMS messages to you.
Because we value your privacy, we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act.
Online Privacy Policy Policy
This online privacy policy applies to information collected through our website and social media platforms.
Contacting Us
If there are any questions regarding this privacy policy or disclaimer you may reply to this email.
Disclaimer
BroadStreetAlerts. com is a wholly owned subsidiary of Small Cap Specialists LLC, herein referred to as SCS LLC.
This website / media webpage is owned, operated, and edited by Small Cap Specialists LLC. Any wording found on this website / media webpage or disclaimer referencing to “I” or “we” or “our” or “SCS LLC” refers to Small Cap Specialists LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and promote public companies. By reading our website / media webpage you agree to the terms of our disclaimer, which are subject to change at any time.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. SCS LLC’s business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our Websites, Email, SMS, Push Notifications, Influencers, Social Media Postings, Ticker Tags, Press Releases, Online or Phone Interviews, Podcasts, Videos, Audio Ads, Banner Ads, Native Ads, Responsive Ads. This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. Note, we periodically conduct interviews and issue stock alerts that we are not compensated for, these are purely for the purpose of building our brands. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct.
Please Note: SCS LLC and its employees are not a registered investment advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold SCS LLC, its operator’s , owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information in our website / media webpage is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, SCS LLC often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. Some of our claims regarding gains could be based on intra-day, pre-market and after-hours trading data.
All information on featured companies is provided by the companies profiled or is available from public sources and SCS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead SCS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.
SCS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and SCS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in small and micro-cap growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, SCS LLC has relied upon information supplied by its customers, publicly available information, and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, SCS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement.
SCS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.
SCS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. SCS LLC is not a Broker/Dealer and does not engage in high frequency trading.

 

 

Most Publicly Traded Companies Engage in Some Form of Paid Media, Investor Relations and Advertising. 

Copyright © 2023 · Broad Street Alerts · All Rights Reserved

Manage Cookie Consent
We use cookies to optimize our website and your experience.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
View preferences
{title} {title} {title}